KR20170091096A - 세르핀 융합 폴리펩티드 및 이의 사용 방법 - Google Patents

세르핀 융합 폴리펩티드 및 이의 사용 방법 Download PDF

Info

Publication number
KR20170091096A
KR20170091096A KR1020177014414A KR20177014414A KR20170091096A KR 20170091096 A KR20170091096 A KR 20170091096A KR 1020177014414 A KR1020177014414 A KR 1020177014414A KR 20177014414 A KR20177014414 A KR 20177014414A KR 20170091096 A KR20170091096 A KR 20170091096A
Authority
KR
South Korea
Prior art keywords
leu
lys
val
glu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020177014414A
Other languages
English (en)
Korean (ko)
Inventor
브렌단 피. 에켈만
존 씨. 티머
퀸 데브루
Original Assignee
인히브릭스 엘피
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/524,832 external-priority patent/US10400029B2/en
Application filed by 인히브릭스 엘피 filed Critical 인히브릭스 엘피
Priority to KR1020237043666A priority Critical patent/KR20240005109A/ko
Publication of KR20170091096A publication Critical patent/KR20170091096A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K47/48384—
    • A61K47/48546—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
KR1020177014414A 2014-10-27 2015-10-27 세르핀 융합 폴리펩티드 및 이의 사용 방법 Ceased KR20170091096A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237043666A KR20240005109A (ko) 2014-10-27 2015-10-27 세르핀 융합 폴리펩티드 및 이의 사용 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/524,832 2014-10-27
US14/524,832 US10400029B2 (en) 2011-06-28 2014-10-27 Serpin fusion polypeptides and methods of use thereof
PCT/US2015/057533 WO2016069574A1 (en) 2014-10-27 2015-10-27 Serpin fusion polypeptides and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237043666A Division KR20240005109A (ko) 2014-10-27 2015-10-27 세르핀 융합 폴리펩티드 및 이의 사용 방법

Publications (1)

Publication Number Publication Date
KR20170091096A true KR20170091096A (ko) 2017-08-08

Family

ID=55858243

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177014414A Ceased KR20170091096A (ko) 2014-10-27 2015-10-27 세르핀 융합 폴리펩티드 및 이의 사용 방법
KR1020237043666A Ceased KR20240005109A (ko) 2014-10-27 2015-10-27 세르핀 융합 폴리펩티드 및 이의 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237043666A Ceased KR20240005109A (ko) 2014-10-27 2015-10-27 세르핀 융합 폴리펩티드 및 이의 사용 방법

Country Status (15)

Country Link
EP (1) EP3212290A4 (enExample)
JP (2) JP6737781B2 (enExample)
KR (2) KR20170091096A (enExample)
CN (2) CN114316068A (enExample)
AU (3) AU2015339507B2 (enExample)
BR (1) BR112017008525A2 (enExample)
CA (1) CA2965151A1 (enExample)
HK (1) HK1244460A1 (enExample)
IL (2) IL251799B2 (enExample)
MX (2) MX2017005467A (enExample)
NZ (1) NZ769391A (enExample)
RU (1) RU2746550C2 (enExample)
SG (2) SG11201703390SA (enExample)
UA (1) UA127305C2 (enExample)
WO (1) WO2016069574A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210111245A (ko) * 2018-10-29 2021-09-10 스핀 테라퓨틱스, 엘엘씨 알파-1-항트립신 장애들을 위한 조성물들 및 방법들
CN111989340B (zh) * 2018-11-18 2025-07-15 杭州博虎生物科技有限公司 一种重组人白细胞介素-10融合蛋白及其应用
CN112315897A (zh) * 2020-11-04 2021-02-05 深圳前海鹰岗生物科技有限公司 一种抑制细胞炎症反应释放治疗痛风急性发作的聚合物微针及制备方法
US20240067703A1 (en) * 2020-12-21 2024-02-29 Macquarie University Treatment of glaucoma
GB202102258D0 (en) * 2021-02-17 2021-03-31 Arecor Ltd Novel composition
US20240139296A1 (en) * 2021-03-03 2024-05-02 Formycon Ag Formulations of ace2 fc fusion proteins
CN113325181A (zh) * 2021-04-25 2021-08-31 苏州市立医院(北区) 丝氨酸蛋白酶抑制剂在用于脓毒症早期预警的标志物中的应用
CN119638849A (zh) * 2021-10-18 2025-03-18 深圳科兴药业有限公司 一种生长激素融合蛋白及其应用
JP2025518537A (ja) 2022-05-16 2025-06-17 サノフィ エーエーティーディー インコーポレイテッド 対象のＡＡＴ欠損症を治療する方法に使用するための有効量の組換えセルピン－Ｆｃ融合タンパク質
AU2024219542B1 (en) * 2023-05-05 2024-10-03 Ashley Maurice Buckle Novel therapeutic polypeptide

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3609300A (en) * 1999-03-01 2000-09-21 Human Genome Sciences, Inc. Human serpin proteins
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CN102020700A (zh) * 2003-07-18 2011-04-20 沃泰克斯药物股份有限公司 丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂
PL2520654T3 (pl) * 2003-08-26 2017-08-31 The Regents Of The University Of Colorado, A Body Corporate Inhibitory aktywności proteazy serynowej i ich zastosowanie w sposobach i kompozycjach do leczenia zakażeń bakteryjnych
EP2314618A3 (en) * 2004-11-12 2011-10-19 Xencor Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) * 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
WO2010080538A1 (en) * 2008-12-19 2010-07-15 Macrogenics, Inc. Covalent diabodies and uses thereof
EP1910542B1 (en) * 2005-07-22 2009-12-02 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
CN101443357A (zh) * 2005-08-12 2009-05-27 先灵公司 Mcp1融合物
CA2729012A1 (en) * 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
DK2654780T3 (en) * 2010-12-23 2017-04-10 Janssen Biotech Inc ACTIVE PROTEASE-RESISTANT ANTIBODY-FC MUTANTS
KR20160044598A (ko) * 2011-03-29 2016-04-25 로슈 글리카트 아게 항체 Fc 변이체
AU2012275295B2 (en) * 2011-06-28 2016-11-10 Inhibrx, Lp WAP domain fusion polypeptides and methods of use thereof
LT2726092T (lt) * 2011-06-28 2019-10-10 Inhibrx, Lp Sulieti serpino polipeptidai ir jų panaudojimo būdai
CA2896951A1 (en) * 2012-01-10 2013-07-18 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
CN104582736A (zh) * 2012-06-21 2015-04-29 印第安纳大学研究及科技有限公司 Fc效应子功能改变的肠降血糖素受体配体多肽Fc区融合多肽和缀合物
JP6309002B2 (ja) * 2012-06-27 2018-04-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 標的に特異的に結合する少なくとも１つの結合実体を含む抗体Ｆｃ領域結合体を作製するための方法およびその使用
MX2015000681A (es) * 2012-08-02 2015-04-10 Hoffmann La Roche Metodo para producir receptores de fc (fcr) solubles como fusion de fc con region de fc de inmunoglobulina inerte y uso de las mismas.
US9758807B2 (en) * 2012-12-05 2017-09-12 SOLA Biosciences, LLC Protein expression enhancing polypeptides

Also Published As

Publication number Publication date
AU2015339507B2 (en) 2021-07-01
IL251799B2 (en) 2024-04-01
HK1244460A1 (zh) 2018-08-10
WO2016069574A1 (en) 2016-05-06
KR20240005109A (ko) 2024-01-11
BR112017008525A2 (pt) 2018-01-30
IL251799A0 (en) 2017-06-29
NZ769391A (en) 2024-12-20
RU2017118325A (ru) 2018-11-29
CN107206257A (zh) 2017-09-26
MX2021012047A (es) 2021-11-03
UA127305C2 (uk) 2023-07-19
EP3212290A4 (en) 2019-01-23
EP3212290A1 (en) 2017-09-06
RU2017118325A3 (enExample) 2019-03-21
AU2024203586A1 (en) 2024-06-20
CA2965151A1 (en) 2016-05-06
RU2746550C2 (ru) 2021-04-15
AU2021240153A1 (en) 2021-10-28
IL251799B1 (en) 2023-12-01
MX2017005467A (es) 2017-11-30
JP6737781B2 (ja) 2020-08-12
JP2020180157A (ja) 2020-11-05
IL308589A (en) 2024-01-01
SG11201703390SA (en) 2017-05-30
NZ731223A (en) 2024-12-20
JP2017537888A (ja) 2017-12-21
AU2015339507A1 (en) 2017-05-11
SG10201903142RA (en) 2019-05-30
CN114316068A (zh) 2022-04-12

Similar Documents

Publication Publication Date Title
AU2021202131B2 (en) Serpin fusion polypeptides and methods of use thereof
AU2015339507B2 (en) Serpin fusion polypeptides and methods of use thereof
US11046752B2 (en) Serpin fusion polypeptides and methods of use thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20170526

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PN2301 Change of applicant

Patent event date: 20200220

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201027

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230118

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230717

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230118

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20230717

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20230320

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20201027

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20240108

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20231218

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20230717

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20230320

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20230118

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20201027

X601 Decision of rejection after re-examination